"With antibiotics, you're potentially targeting 8-10 pathogens, and each of these pathogens cause infections in different settings...each one of these pathogens has a different resistance mechanism, too," said Mahesh Patel, a chief scientific officer at Indian pharmaceutical company, Wockhardt.
Pharmaceutical companies in lower and middle-income regions are taking a localized approach testing so-called 'candidate' antibiotics locally, where there is a specific need among communities they know well.
There is a dire need for new antibiotics amid growing antimicrobial resistance (AMR), especially in low-and-middle income countries.
It takes more time and is more costly to develop and produce antibiotics than vaccines, antibiotics are very complex."
#antibiotic-resistance #global-health #drug-development #low-income-countries #pharmaceutical-industry
Collection
[
|
...
]